Semipermanent filler treatment of hiv-positive patients with facial lipoatrophy: Long-term follow-up evaluating MR imaging and quality of life

Aesthetic Surgery Journal

Volumn 34, Issue 1, 2014, Pages 118-132

  Van Rozelaar, Leo ^a   Kadouch, Jonathan A ^b   Duyndam, Debbie A ^c   Nieuwkerk, Pythia T ^d   Lutgendorff, Femke ^d   Karim, Refaat B ^a  

^a VU Medical Centre ^*

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

combination antiretroviral therapy; cosmetic medicine; facial; fillers; HIV; lipoatrophy; MRI; quality of life

Indexed keywords

ANTIBIOTIC AGENT; FILLER; HYDROXYAPATITE; POLYLACTIC ACID;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEPRESSION; FEMALE; FOLLOW UP; HEMATOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INFLAMMATION; LIPOATROPHY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SELF REPORT; SHORT FORM 36; SKIN NODULE; SOCIAL INTERACTION; TISSUE EXPANSION;

COMBINATION ANTIRETROVIRAL THERAPY; COSMETIC MEDICINE; FACIAL; FILLERS; HIV; LIPOATROPHY; MRI; QUALITY OF LIFE;

ADULT; AGED; BIOCOMPATIBLE MATERIALS; COSMETIC TECHNIQUES; DURAPATITE; FACE; FEMALE; HIV SEROPOSITIVITY; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INJECTIONS, SUBCUTANEOUS; LACTIC ACID; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POLYMERS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; SUBCUTANEOUS FAT; TIME FACTORS; TREATMENT OUTCOME;

EID: 84891847420     PISSN: 1090820X     EISSN: 1527330X     Source Type: Journal    
DOI: 10.1177/1090820X13515270     Document Type: Article

References (27)

1. Blanch J, Rousaud A, Martinez E, et al. Impact of lipodystrophy on the quality of life of HIV-1-infected patients. J Acquir Immune Defic Syndr. 2002 ; 31 (4). 404-407
2. Blanch J, Rousaud A, Martinez E, et al. Factors associated with severe impact of lipodystrophy on the quality of life of patients infected with HIV-1. Clin Infect Dis. 2004 ; 38 (10). 1464-1470
3. Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS. 2001 ; 15 (11). 1389-1398
4. Ribera E, Paradineiro JC, Curran A, et al. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study). HIV Clin Trials. 2008 ; 9 (6). 407-417
5. Duran S, Saves M, Spire B, Cailleton V. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 2001 ; 15 (18). 2441-2444
6. Valantin MA, Lanoy E, Bentata M, et al. Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial. HIV Med. 2008 ; 9 (8). 625-635
7. Grunfeld C, Saag M, Cofrancesco J, et al. Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy. AIDS. 2010 ; 24 (11). 1717-1726
8. Sheth SH, Larson RJ. The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. BMC Infect Dis. 2010 ; 10: 183
9. Calmy A, Bloch M, Wand H, et al. No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial. HIV Med. 2010 ; 11 (8). 493-501
10. Mallon PW, Miller J, Kovacic JC, et al. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men - a randomized, placebo-controlled study. AIDS. 2006 ; 20 (7). 1003-1010
11. Karim RB, de Lint CA, van Galen SR, et al. Long-term effect of polyalkylimide gel injections on severity of facial lipoatrophy and quality of life of HIV-positive patients. Aesthetic Plast Surg. 2008 ; 32 (6). 873-878
12. Moyle GJ, Lysakova L, Brown S, et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med. 2004 ; 5: 82-87
13. Hillebrand ME, Strackee SD, van Ulden BJG, et al. Behandeling van lipoatrofie in het gelaat met L-polymelkzuur: de PLA-studie. Ned Tijdschr Geneeskd. 2002 ; 146: 2274-2275
14. Lam SM, Azizzadeh B, Graivier M. Injectable poly-L-lactic acid (Sculptra): technical considerations in soft-tissue contouring. Plast Reconstr Surg. 2006 ; 118: 55S - 63S
15. Carruthers A, Carruthers J. Evaluation of injectable calcium hydroxylapatite for the treatment of facial lipoatrophy associated with human immunodeficiency virus. Dermatol Surg. 2008 ; 34 (11). 1486-1499
16. Sturm LP, Cooter RD, Mutimer KL, et al. A systematic review of permanent and semipermanent dermal fillers for HIV-associated facial lipoatrophy. AIDS Patient Care STDs. 2009 ; 23 (9). 699-714
17. James J, Carruthers A, Carruthers J. HIV-associated facial lipoatrophy. Dermatol Surg. 2002 ; 28 (11). 979-986
18. Kadouch JA, van Rozelaar L, Karim RB, Hoekzema R. Current treatment methods for combination antiretroviral therapy-induced lipoatrophy of the face. Int J STD AIDS. 2013 ; 24 (9). 685-694
19. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36), I: conceptual framework and item selection. Med Care. 1992 ; 30: 473-483
20. Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study: preliminary validation in persons with early HIV infection. Med Care. 1991 ; 29: 786-798
21. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977 ; 1: 385-401
22. Valantin MA, Aubron-Olivier C, Ghosn J, et al. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS. 2003 ; 17 (17). 2471-2477
23. Silvers SL, Eviatar JA, Echavez MI, Pappas AL. Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability. Plast Reconstr Surg. 2006 ; 118 (3). 34S - 45S
24. Schelke LW, Van Den Elzen HJ, Erkamp PP, Neumann HA. Use of ultrasound to provide overall information on facial fillers and surrounding tissue. Dermatol Surg. 2010 ; 36: 1843-1851
25. Wortsman X, Wortsman J, Orlandi C, Cardenas G, Sazunic I, Jemec GB. Ultrasound detection and identification of cosmetic fillers in the skin. J Eur Acad Dermatol Venereol. 2012 ; 26 (3). 292-301
26. Feeney JN, Fox JJ, Akhurst T. Radiological impact of the use of calcium hydroxylapatite dermal fillers. Clin Radiol. 2009 ; 64 (9). 897-902
27. Carruthers A, Liebeskind M, Carruthers J, Forster BB. Radiographic and computed tomographic studies of calcium hydroxylapatite for treatment of HIV-associated facial lipoatrophy and correction of nasolabial folds. Dermatol Surg. 2008 ; 34: S78 - S84